NASDAQ: XAIR
Beyond Air Inc Stock

$2.21-0.01 (-0.45%)
Updated Sep 2, 2025
XAIR Price
$2.21
Fair Value Price
N/A
Market Cap
$11.55M
52 Week Low
$2.02
52 Week High
$13.52
P/E
-0.2x
P/B
1.16x
P/S
3.61x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.78M
Earnings
-$42.12M
Gross Margin
-24.6%
Operating Margin
-826.24%
Profit Margin
-880.7%
Debt to Equity
1.78
Operating Cash Flow
-$33M
Beta
0.98
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

XAIR Overview

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine XAIR's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
D
XAIR
Ranked
#88 of 111

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$56.92A
$7.22A
$36.90A
View Top Medical Device Stocks

Be the first to know about important XAIR news, forecast changes, insider trades & much more!

XAIR News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XAIR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

XAIR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XAIR is good value based on its book value relative to its share price (1.16x), compared to the US Medical Devices industry average (4.05x)
P/B vs Industry Valuation
XAIR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more XAIR due diligence checks available for Premium users.

Valuation

XAIR fair value

Fair Value of XAIR stock based on Discounted Cash Flow (DCF)

Price
$2.21
Fair Value
-$1.10
Undervalued by
301.62%
XAIR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

XAIR price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.2x
Industry
32.36x
Market
34.73x

XAIR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.16x
Industry
4.05x
XAIR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

XAIR's financial health

Profit margin

Revenue
$1.8M
Net Income
-$7.7M
Profit Margin
-437%
XAIR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
XAIR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$28.1M
Liabilities
$17.7M
Debt to equity
1.78
XAIR's short-term assets ($14.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XAIR's short-term assets ($14.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XAIR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
XAIR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.5M
Investing
$576.0k
Financing
$4.1M
XAIR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

XAIR vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
XAIRD$11.55M-0.45%-0.20x1.16x
WOK$11.66M+1.40%-2.85x0.90x
DHAI$11.36M-9.09%N/A-0.30x
SSKN$11.80M+18.91%-1.00x38.33x
PTHLC$12.11M+16.44%-16.35x1.96x

Beyond Air Stock FAQ

What is Beyond Air's quote symbol?

(NASDAQ: XAIR) Beyond Air trades on the NASDAQ under the ticker symbol XAIR. Beyond Air stock quotes can also be displayed as NASDAQ: XAIR.

If you're new to stock investing, here's how to buy Beyond Air stock.

What is the 52 week high and low for Beyond Air (NASDAQ: XAIR)?

(NASDAQ: XAIR) Beyond Air's 52-week high was $13.52, and its 52-week low was $2.02. It is currently -83.66% from its 52-week high and 9.41% from its 52-week low.

How much is Beyond Air stock worth today?

(NASDAQ: XAIR) Beyond Air currently has 5,226,213 outstanding shares. With Beyond Air stock trading at $2.21 per share, the total value of Beyond Air stock (market capitalization) is $11.55M.

Beyond Air stock was originally listed at a price of $117.50 in May 8, 2019. If you had invested in Beyond Air stock at $117.50, your return over the last 6 years would have been -98.12%, for an annualized return of -48.43% (not including any dividends or dividend reinvestments).

How much is Beyond Air's stock price per share?

(NASDAQ: XAIR) Beyond Air stock price per share is $2.21 today (as of Sep 2, 2025).

What is Beyond Air's Market Cap?

(NASDAQ: XAIR) Beyond Air's market cap is $11.55M, as of Sep 3, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Beyond Air's market cap is calculated by multiplying XAIR's current stock price of $2.21 by XAIR's total outstanding shares of 5,226,213.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.